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Abstract
The estimated shelf life of a drug product is highly influenced by the variability of the measured data.
The fluctuation of the stability data is composed of the manufacturing process variation (batch-to-
batch and within batch variability) and of the uncertainty of the analytical method (reproducibility
and repeatability). The aim of the paper is to show a calculation method by which all of the variance
components can be estimated before commencing the stability study. The effect of the uncertainty
on the estimated shelf life is also considered: the expected variance of a single stability time point
and the width of the 95% one-sided confidence limit after 2 storage years are calculated. For the
computation the results of the content uniformity test and the validation (specifically the precision
study) of the analytical method are used. The applied mathematical method is the analysis of variance.
The advantage of the concept is that if the magnitude of the uncertainty is known in advance, one may
consider whether the present manufacturing process and analytical method is suitable for the stability
study.
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1. Introduction
In the pharmaceutical industry stability study is performed to estimate the shelf life
of a drug product. The purpose of the stability study is to provide evidence on
how the quality of a drug product varies with time under the influence of a variety
of environmental factors such as temperature, humidity and light, and to establish
the shelf life for the drug product and the recommended storage conditions [6].
A complete stability design includes accelerated and long term stability testing.
Stability data obtained from the long term testing are used directly for the shelf life
estimation, so this paper focuses only on the long term stability testing. The shelf
life estimation is usually performed in the early stage of drug development, when
limited number of stability data is available.
There are three steps in the stability analysis [8]. The first step is to collect
the stability data at several time intervals for the samples stored under appropriate
conditions. Stability data should cover all of those attributes of the drug product
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that are susceptible to change during the storage and are likely to influence quality,
safety and efficacy [6]. For the sake of brevity we concentrate here only on the
active ingredient content analyses. The second step of the analysis is to choose
the adequate model to describe the relationship between the measured data and the
storage time. In this paper we assume that the assay content of the drug product
decreases linearlywith time, which is the commonly applied approach for describing
the degradation of active ingredients [2]. The third step of the analysis is to estimate
the shelf life based on the information from all batches assayed. According to the
ICH Guideline [5] for an attribute known to decrease with time (e.g. the active
ingredient content), the shelf life of the drug product is calculated as the time point
where the lower one-sided 95% confidence limit for the mean degradation curve
intersects the minimal required content. In most cases there is also an upper limit,
which may cause troubles even if there is no real increase in assay content. This
problem is not dealt with in this paper. The width of the confidence band depends
on the number of experimental points, thus it would be advantageous to combine
the data from the batches. Pooling the data should be supported by preliminary
testing of batch similarity. The α value for these statistical tests is usually taken
as 0.25. If the tests for equality of slopes and intercepts are accepted, the shelf
life estimation is based on the pooled data. However, if the hypothesis of batch
similarity is rejected, the shelf life is determined on the basis of the minimum of
individual shelf lives obtained for each batch.
The method of the ICHGuideline has been criticized by several papers. Some
papers contest the justness of the 0.25 significance level for the preliminary testing
[10, 13]. CHOW and SHAO [4] state that if there is batch-to-batch variation, the
shelf life estimated on the basis of one (the worst) batch does not represent the
shelf life of all future batches manufactured under similar conditions. Thus the
random effects model seems more adequate than the assumption of the fixed batch
effect [3, 11]. In this paper the fixed effects model was used, however. There are
several proposals to estimate model parameters of the stability study and consider
adequately the error structure. In our former paper [7] a modified random error
model was proposed for the shelf life estimation.
This paper accepts the Guideline model in respect that how the uncertainty of
the stability data influences the shelf life estimation. The shelf life is the point of
intersection of the confidence limit and the acceptance criterion. Assuming linear
function, the two-sided confidence limits for a given time point (x) are given as:
yˆ − tα/2sy
√
1
n
+ x − x¯)
2∑
j (x j − x¯)2
< y < yˆ + tα/2sy
√
1
n
+ (x − x¯)
2∑
j (x j − x¯)2
, (1)
where yˆ is the estimated value at the given time point, tα/2 is the Student’s t coeffi-
cient at α (two-sided) risk and n−2 degrees of freedom, sy is the standard deviation
of the measured data, n is the number of the time points, xj is the j th time point and
x¯ is the mean of the time points. As it is seen from the equation above the width
of the confidence band and thus the shelf life depends on the standard deviation of
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the measured data (sy). This means that highly variable stability data reduce the
estimated shelf life.
Although the variability of the stability data is a common reality, the effect
of the manufacturing and analytical method uncertainty on the shelf life has been
studied only in a few articles. BAR [1] divided the reasons for change of measured
data into two parts: the decrease of assay during the storage period and the random
variation of the analytical method. He estimated the repeatability and reproducibil-
ity of an analytical method using the data from stability study of a stable drug.
VAN DER VEEN et al. [12] discussed the uncertainty components of a stability
study of certified reference materials in detail and showed how these components
could be determined from the stability study itself. PAUWELS et al. [9] carried
out a lot of simulations with different degradation rates, coefficients of variation
and confidence levels to demonstrate the effect of these parameters on the shelf life
estimation.
In the papers mentioned the variance components of the uncertainty have been
estimated from the stability study (of a drug product or a certified referencematerial)
itself. It would be, however, useful to obtain the expected uncertainty of the stability
data before the start of the stability study, because if themagnitude of the uncertainty
is known in advance, one may consider whether the present manufacturing process
and analytical method is suitable for the stability study. Thus, the aim of this paper
is to show a calculation method, by which all of the uncertainty components can
be estimated before the start of the stability study and their effect on the shelf life
estimation is considered in advance.
2. Method of Calculation
The fluctuation of the stability data is composed of the manufacturing process
variation and the uncertainty of the analytical method. For the computation the
following elementary variance components are taken into consideration:
• batch-to-batch variability (σ2batch),
• heterogeneity within each batch (σ2heterogeneity),
• period-to-period variability (σ2circumstances, for example σ
2
day or σ
2
lab),
• replicate-to-replicate variability (σ2error).
The batch-to-batch and the within batch variability belong to the manufactur-
ing process variation. Consideration of the effect of these variance components is
justified, because during a stability study several (usually three) batches are tested
and at each time point or replicate different tablets are analysed.
The other two variance components join to the uncertainty of the analytical
method. The replicate-to-replicate variability is characterized with the repeatability
of the analytical method. The period-to-period variability is in principle reflected
by the intra-laboratory reproducibility (intermediate precision), when the analytical
method is replicated on different days. This analysis is generally performed on
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days in succession. Opposite to this at the stability study several months are gone
between the dates of analysis, so the circumstances of the measurements (e. g.
analysts, equipments, reagents) may differ more from each other. We consider
therefore that the scenario of performing analysis in so much different time points
is often represented more adequately by the inter-laboratory reproducibility (when
the analytical method is replicated under completely different conditions).
To estimate the contribution of these variance components to the total variance
results of two kinds of analyses of the analytical developing procedure may be
used: the content uniformity test and the validation of the analytical method. These
analytical measurements are normally performed during the development of a drug
product, thus no extra analysis is required to the calculation.
Content Uniformity Test
During the content uniformity test 10–10 tablets from usually 3 batches are analysed
individually. By analysis of variance two variance components can be separated:
σbatch, which is the effect of batch-to-batch variability and σ2tablet, which includes
both the effect of heterogeneity and the replicate-to-replicate variability. The effect
of heterogeneity and the replicate-to-replicate variability can not be separated from
one another, because the tablets are shattered during the analytical measurement, so
the analysis may not be repeated with the same tablet. Since the tablets are analysed
individually, the σ2tablet variance component is a simple combination of the effect of
heterogeneity and the replicate-to-replicate variability:
σ 2tablet = σ 2heterogeneity + σ 2error. (2)
Validation of the Analytical Method
The main objective of the validation of an analytical method is to demonstrate that
the procedure is suitable for its intended purpose. One of the examined validation
characteristics is the precision, which is the measure of the random error. The
determination of the precision may be subdivided into three steps: the examination
of repeatability, intermediate precision and reproducibility.
Repeatability Study
Repeatability defines the ability to repeat the same analytical methodology by the
same analyst, using the same equipment in the same laboratory, within the same
day. Evaluating the data σ2repeatability variance is given. This variance contains both
the effect of heterogeneity and the replicate-to-replicate variability, because the
determination of repeatability (similarly to the content uniformity test) may not be
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repeated with the same tablets. However, opposite to the content uniformity test,
during the testing of repeatability a mixture of several (usually 4–6) tablets are
analysed within one replicate. In this case Eq. (2) is to be modified, because the
effect of heterogeneity is averaged for replicates:
σ 2repeatability = σ 2heterogeneity/p + σ 2error, (3)
where p is the number of the tablets used at one replicate.
It should be noted, that the above equation is valid only in cases when the
repeated measurements are always performed from new tablets. If the same homog-
enized pool of tablets is used for the repetition, the heterogeneity does not come
into the picture, so the above relationship becomes simpler: σ2repeatability = σ 2error.
Sometimes even in case of homogenized sample the preparation method may have
inherent bias, this will not be considered here.
To separate the effect of heterogeneity from the replicate-to-replicate vari-
ability the difference between the content uniformity test and the determination of
repeatability can be applied. Using the Eq. (2) and (3) the effect of heterogeneity
(σ 2heterogeneity) and the replicate-to-replicate variability (σ
2
error) are separately given:
σ 2heterogeneity = (σ 2tablet − σ 2repeatability)/(1 − 1/p) (4)
σ 2error = σ 2tablet − σ 2heterogeneity. (5)
Intermediate Precision Study
Intermediate precision is the ability to replicate the same analytical methodology
in the same laboratory, but by different analysts or using different equipment or
performing on different days. Analysis of variance leads to two variance compo-
nents: σ 2circumstances refers to the different circumstances, while σ
2
repeatability concerns
the repeatability under the same conditions. The variance component of different
circumstances shows either the effect of different analysts (σ2person) or equipments
(σ 2equipmemt) or days (σ
2
day).
Reproducibility Study
Reproducibility is the ability to repeat the same analytical methodology under com-
pletely different conditions: namely in different laboratories by obviously different
analysts, using different equipments. Two variance components are given by analy-
sis of variance: σ2lab belongs to the different laboratories and σ
2
repeatability characterizes
the repeatability under the same conditions.
It is apparent that from the precision study several (exactly three) estimates
for σ 2repeatability variance component are given, namely from the examinations of
repeatability, intermediate precision and reproducibility.
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Table 1 summarises the two steps of the variance component estimation de-
scribed above. The second and the third columns show the relationship between
the estimated and the elementary variance components. It is worth mentioning
that naturally only the estimates of these variances (σˆ2) are available, they may be
calculated from the measured data.
Table 1. The estimation method of the variance components
Analytical measurements
The determined
variance component
The elementary
variance component
Content uniformity test
σ 2batch σ
2
batch
σ 2tablet σ
2
heterogeneity and σerror
Validation
Precision study
σ 2day σ
2
day
σ 2lab σ
2
lab
σ 2repeatability σ
2
heterogeneity and σ
2
error
The Effect of the Uncertainty of the Stability Data on the Shelf Life Estimation
In this section it is outlined how the manufacturing and analytical method uncer-
tainty influences the shelf life estimation. The first step of the computation is to
determine the expected variance (σˆ2) of a single stability time point. The estimated
elementary variance components mentioned in Table 1 are used to the calculation:
σˆ 2 =
σˆ 2error +
σˆ 2heterogeneity
p
r
+ σˆ 2batch + σˆ 2day + σˆ 2lab, (6)
where r is the number of replicates at each time point. If the calculation is based on
a single batch (batches are treated separately), σ2batch is obviously not considered.
Eq. (1) contains the standard deviation of stability data, usually obtained in
the course of regression analysis. As our intent is to predict this standard deviation,
but without having the stability data themselves, the σˆ2 value calculated by Eq. (6)
is inserted in two ways into Eq. (1). In both cases stability study was modelled
assuming linear degradation of the active ingredient content. The effect of the
uncertainty was characterized by the width of the confidence limit.
In the first approach the square root of the estimated overall variance resulted
by Eq. (6) was taken as sy standard deviation. The assumed degrees of freedom
is equal to the degrees of freedom of sy as if it were estimated in the course of
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regression analysis of stability data. The other parts of Eq. (1) are determined by
the design of the stability study.
In the second approach the estimated elementary variance components (σ2error,
σ 2heterogeneity, σ
2
batch, σ
2
day, σ
2
lab) were taken as variances and a simulation study was
performed to produce stability data (concentration values at different time points).
The simulated points obtained this way reflect all the sources of fluctuation as if they
were really measured. Then a straight line was fitted to the data and the confidence
limit was calculated using the residual standard deviation.
3. Example
In this part concrete examples are shown to illustrate the process of the estimation
of the variance components and to see the effect of the uncertainty of the stability
data on the shelf life estimate.
These specific examples contain data on drug products where there is serious
matrix effect in analysis. In addition the active ingredient content is low in the
products, thus the analysis is a difficult task. The active ingredient content of the
two drug products (A and B) was determined by an HPLC method. Details and
source of the data are not given for confidentiality reason.
The design of the precision study was composed of the following steps. The
determination of repeatability was performed with 6 repeated measurements under
the same conditions. For the determination of intermediate precision 3 repeated
measurements were carried out on 3 different days. During the determination
of reproducibility the analytical method was repeated in 2 different laboratories
performing 6–6 measurements in each laboratory on one day. At each replicate
above 5–5 tablets were homogenised and analysed from a batch.
The determination of intermediate precision was also performed by individual
tablets: 10–10 tablets were analysed individually on 3 different days. The results
of this analysis were used to estimate the heterogeneity.
4. Results and Discussion
4.1. Variance Component Estimation
Estimation of the Repeatability Variance Component
The repeatability variance component can be estimated from all the three kinds
of examinations of the precision study. The results performed by ANOVA are
summarized in Table 2. The last row of the table contains the pooled mean square
values from the three repeatability variance components.
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Table 2. The estimated variance components of repeatability (assay %)
The source of the variance σˆ 2repeatability
component estimation A B
Repeatability study 1.67 1.13
Intermediate precision study 0.71 0.76
Reproducibility study 1.38 1.27
Pooled mean square 1.26 1.09
Estimation of the Effect of Days
The variance component regarding the days can be estimated from the examina-
tion of intermediate precision. The results are summarized in Table 3. As the
intermediate precision study was performed both for individual tablets and samples
containing more tablets, we have two estimates per drug products for the effect of
days.
Table 3. The estimated variance components of the days (assay %)
The source of the variance σˆ 2day
component estimation A B
Intermediate precision study 4.48 1.81
Intermediate precision study
for individual tablets
3.76 0
If the estimates shown in Table 3 are compared row by row, it can be proved
that the variance components estimated from the intermediate precision study for
individual tablets are lower. The reason for this is that comparing two designs of
experiments for the observation of the same effect of a factor by one-way ANOVA
is more difficult when the error (within) mean square is higher. At the examination
of individual tablets the repeatability mean square is much higher due to the greater
heterogeneity variance component, so the effect of the days can be observed with
only lower probability.
It is also apparent from Table 3, that the days of analysis have a significant
effect on the measured data. At the active ingredient A the variation caused by the
days is particularly high.
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Estimation of Reproducibility
The data from the determination of reproducibility were evaluated using one-way
ANOVA. It was found that at this analytical method the laboratory as a factor has
no effect on the measured data at 5% significance level.
Estimation of the Effect of Heterogeneity
The intermediate precision study for individual tablets is (similarly to the content
uniformity test) also suitable for the estimation of the effect of heterogeneity. From
the data the σ2tablet variance component can be given directly.
For the separation of the effect of heterogeneity from the replicate-to-replicate
(error) variability Eq. (4) and (5) is used. The results summarized in Table 4 show
that at these drug products the effect of heterogeneity is much higher than the
replicate-to-replicate variability.
Table 4. The estimated variance components belonging to the individual assay determi-
nation and the results of the separation of the effect of heterogeneity and the
replicate-to-replicate variability (assay %)
A B
σˆ 2tablet 5.44 4.73
σˆ 2heterogeneity 5.23 4.55
σˆ 2error 0.21 0.18
The variance components given in Tables 2–4 are only point estimates of
the theoretical value. Because of the few replicates these point estimates have a
great uncertainty. The effect of the uncertainty will be considered by the shelf life
calculation of the drug product.
4.2. Use of Variance Components in Assessing a Virtual Design
Let us consider a general stability design, when 3 batches are tested and the testing
frequency is every 3rd month over the first year. At each time point 3 repeated
measurements are performed and at each replicate 5–5 tablets are homogenized
and analyzed once.
The expected uncertainty of the stability data is characterizedwith the variance
of a single time point and the width of the 95% one-sided confidence limit after 2
storage years. All calculations are performed for two cases:
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a. the data of the three batches may not be pooled, so the shelf life estimation
is based on the data of one (the worst) batch,
b. the data of the three batches may be pooled.
Table 5 summarizes the expected variance of a single time point calculated by
Eq. (6) and the width of the confidence limit computed by the first concept, where
sy is the square root of the estimated overall variance. Since σ2batch is not available
at these drug products, an average value (1.5) was used.
Table 5. The uncertainty of a single stability datum point and the calculated confidence
limit after 2 years (assay %)
A B
The batches may
not be pooled
σˆ 2 4.90 2.17
width of the 95% one-sided
confidence limit
10.2 6.8
The batches may
be pooled
σˆ 2 6.40 3.67
width of the 95% one-sided
confidence limit
5.1 3.8
Table 6 shows the results using the second approach (simulation study) for
the “A” active ingredient. Comparing the width of the confidence limit obtained
by the two approaches it can be stated that the order of magnitude of the results is
similar.
Table 6. The results of the simulation study (assay %)
The width of the 95% one-sided
‘A’ active ingredient confidence limit after 2 years
Mean∗ Standard deviation∗
The batches may
not be pooled
8.98 3.84
The batches may
be pooled
4.06 1.24
(∗calculated from the 1000 cases)
The specification limit for the active ingredient content is usually 90–105%
at the end of shelf life. Let us compare this specification limit with the width
of confidence limit given in Table 5 or 6. If the data of the examined batches
may not be pooled and the effect of analysis dates is high (for example at the ‘A’
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active ingredient), the width of confidence limit may be as high as 10%. This
means that even in the favourable case when the initial active ingredient content is
approximately 100% and no degradation occurs, the lower limit of the confidence
bound intersects the specification limit already at the end of the 2nd year. If the
data of the examined batches may be pooled, the width of confidence limit becomes
narrower (3.8–5%). However, if the initial active ingredient content decreases by
5% over 2 years, the 5% width of the confidence limit means that the estimated
shelf life will be also only about 2 years.
It should be also noted that at this analytical method the effect of inter-
laboratory reproducibility was not significant. If σˆ2lab > 0, the expected variance
of a single time point will be even higher and the width of the confidence-limit
becomes wider, because the additional fluctuation caused by different laboratories
(which means completely different conditions of the analytical measurements) may
be also taken into consideration.
5. Conclusions
In the paper a calculation method is shown by which the fluctuation of the stability
data is forecasted. First all of the uncertainty components influencing the variability
of stability data are determined using the results of two analyses (the content uni-
formity test and the validation study) of the developing procedure of a drug product.
At the second step the effect of this uncertainty on the shelf life is estimated.
We stated that the highly variable stability data significantly reduce the esti-
mated shelf life. The results of our examples may not be general, but not unreal.
Thus, it is worth considering the source of the uncertainty at the planning of any
stability and validation studies.
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